Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
162 hedge funds and large institutions have $573M invested in Eagle Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 67 reducing their positions, and 10 closing their positions.
120% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 10
7% more funds holding
Funds holding: 151 → 162 (+11)
13% less capital invested
Capital invested by funds: $659M → $573M (-$86.7M)
28% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 67
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$5.63M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$2.44M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.5M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$1.35M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$829K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$13.2M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$11.4M |
| 3 |
TLP
Tri Locum Partners
New York
|
-$6.83M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$5.37M |
| 5 |
JP Morgan Chase
New York
|
-$4.54M |
EGRX Hedge Fund Activity: Q4 2021 in Review
162 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2021, worth a combined $573M — down 13% from $659M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new EGRX positions and 10 closed out — a net gain of 12 holders — while 48 added to existing stakes and 67 trimmed.
The largest buyer was Ameriprise, adding an estimated $5.63M. The largest seller was Bank of Montreal, exiting entirely with an estimated $13.2M sold.
- 162 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2021, up from 151 in Q3 2021.
- Funds reported $573M of Eagle Pharmaceuticals, Inc. stock for Q4 2021, down 13% quarter-over-quarter.
- 22 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2021 and 10 closed out, a net change of +12 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2021 was Ameriprise, an estimated $5.63M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q4 2021 was Bank of Montreal, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2021.